poisar

Stock

Entrada Therapeutics, Inc. TRDA

$7.25+2.98%

Overview

TRDA market data

Price History

TRDA price chart · 1M
O
7.04
H
7.36
L
7.03
C
7.25
Vol
25,883.00
Source
US equities market feed
Observed
Aug 27, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$7.04
Previous Close
$7.04
Day High
$7.36
Day Low
$7.03
52 Week High
$16.43
52 Week Low
$5.65
7 Day Return
-4.48%
30 Day Return
+24.14%
90 Day Return
+2.84%
1 Year Return
-43.03%
Daily Notional Volume
$187.7K
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$3.47
Diluted earnings per share over the trailing twelve months.
Beta
-0.26
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-3,537.7%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$5.02 – $16.45
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $290.1M · P/B 1.28 · P/S 61.90.

Company News

5 captured
Entrada Therapeutics Q2 EPS $(1.01) Beats $(1.09) Estimate, Sales $898.000K Beat $411.429K EstimateBenzinga · Aug 5, 2026, 11:34 AM
8-K filing — Entrada Therapeutics, Inc. (TRDA)SEC EDGAR · Aug 5, 2026, 11:04 AM
Guggenheim Maintains Buy on Entrada Therapeutics, Lowers Price Target to $17Benzinga · Jun 8, 2026, 2:25 PM
Entrada Advances Duchenne Muscular Dystrophy Drug to Higher Dose Cohort, Safety Review Clears Next Stage of Clinical TrialBenzinga · Jun 2, 2026, 11:17 AM
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 StudyGlobenewswire Inc · Jun 2, 2026, 11:15 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock